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CHAPTER 1 
INTRODUCTION AND LITERATURE 
REVIEW 
Porcine circovirus type 2-associated disease (PCVAD) causes significant economic 
damage in the swine industry. Although other environmental and pathogenic triggers can 
influence the occurrence of PCVAD, PCV2 is the key etiological pathogen for this 
disease (1). The scope of PCV2 incidence in the US national swine herd was evaluated in 
2006 by the National Animal Health Monitoring System (NAHMS), initiated by USDA. 
At that time, which was before vaccines were available in the U.S., over 82% of sera 
from 185 farms were DNA positive and more than 80% were also positive for anti-PCV2 
antibodies, which indicate that PCV2 was widespread and a persistent infection in pigs 
(2). Commercial vaccines have been widely used in US since then. Another NAHMS 
assessment of swine health was carried out in 2012. This thesis is focused on the 
immunologic evaluation of PCV2 status and a determination of both vaccination and 
infection status. 
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Virus	  
History: Porcine circovirus (PCV) was first identified as a contaminant in the porcine 
PK-15 cell line in 1974 (3). The virus was shown to have a diameter of 17 nm, and to 
contain a covalently closed single-stranded DNA (3). The new virus was designated as 
Porcine circovirus type 1 (PCV1) and was found to be nonpathogenic to swine (4), 
although serological surveys revealed there was a high prevalence of PCV1 antibodies in 
the swine population (5). Later, a variant strain of PCV was associated with a newly 
emerged clinical symptom that become known as post-weaning multisystemic wasting 
syndrome (PMWS) (6). Subsequently, nucleotide sequence analysis of the PCV 
associated with cases of wasting syndromes from North America and Europe revealed it 
has an 68% homology with the previously known PCV derived from PK-15 cells, 
indicating these two strains appeared to be closely related but still distinct from each 
other (7, 8). This pathogenic PMWS-associated PCV was then referred to as PCV2 to 
distinguish it from the original PK-15 cell culture isolate, PCV1 (7). A retrospective 
investigation showed that PCV2 was present in pigs in 1962 in Northern Germany (9), 
but not until the late 1990s outbreaks reported simultaneously in various countries (10, 
11). Since then, PCV2-associated disease has become one of the most economically 
significant swine diseases (12). 
Classification: PCV2 is a member of the genus Circovirus in the family Circoviridae, 
which is a non-enveloped virus, consisting of a single-stranded, circular DNA genome (3, 
13). 
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Composition: A total number of 1767-1768 nucleotides comprise the PCV2 genome, of 
which 11 putative open reading frames (ORFs) are predicted (8), but only 4 of which 
have been characterized. 
The largest open reading frame of PCV2 encodes a replicase (Rep) of 312 amino acids 
and its splicing variant Rep’(14)(15). Rep protein alone cannot promote replication; Rep 
and Rep’ together comprise the functional replication initiator factor of PCV2 (16). 
ORF2 of PCV2 encodes the major structure protein, which builds the virus capsid (17). 
The capsid protein has also been identified as the major immunogenic and protective 
protein of PCV2 (18). A 315-bp gene encodes a novel viral protein (ORF3 protein), 
which may be involved in PCV2-induced apoptosis in cultured cells (19), but it has been 
suggested that the pathogenicity of PCV2 is either not determined or not solely 
determined by the ORF3 protein (20). A fourth viral protein, ORF4, is newly discovered. 
ORF4 is not essential for PCV2 replication but plays a role in suppressing caspase 
activity and regulating CD4 (+) and CD8 (+) T lymphocytes during PCV2 infection (21). 
Although many proteins in porcine cells were identified to interact with ORF1 
(Rep/Rep’), ORF2 (Cap), and ORF3 (22-24), a specific molecule or pathway that triggers 
PMWS or other PCVAD has not been fully described (25). 
In 2012, a new agent named P1 was detected by PCR during a diagnostic study of PCV2 
in Hebei and Jiangsu, China (26). The sequenced genome of this porcine circovirus-like 
agent is composed of a 648-nucleotide circular DNA, which includes three predicted 
ORFs (27). Since P1 does not share the replication origin with PCV2, it may be a result 
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of recombination of PCV2 of other organisms rather than rearranged (28). P1 may be a 
new member of the family Circoviridae (27) or possibly a new porcine circovirus (28). 
Genetics: PCV1 and PCV2 have similar genome organization and nucleotide homology 
of approximately 68% (8). At first, a close phylogenetic relationship among global PCV2 
isolates was shown based on nucleotide sequence similarities greater than 93%. The 
methodology of distinguishing PCV2 genotypes depends on the proportion of nucleotides 
sites at which two sequences being compared are different (p distance). This value is 
obtained by dividing the number of nucleotide differences by the total number of 
nucleotides compared. The sequences with nucleotide diversity cut-off of 3.5% could be 
divided into two major groups PCV2a and PCV2b (29). A third genotype (PCV2c) was 
reported from Denmark in the 1980s. Two additional genotypes, PCV2d and PCV2e, 
were suggested (30), however, subsequent analysis of the sequence data could not 
support the new classification (31). 
PCV2a was the most clinically prevalent genotype from 1996 to the early 2000s (32).  
Different countries (Canada, Denmark, Spain, Sweden, Switzerland and USA) have 
described a shift on genotype prevalence from PCV2a to PCV2b, coinciding with the 
advent of the most severe outbreaks of PCVAD (1, 32-37). 
Pigs are also co-infected with these two genotypes. Both PCV2a and PCV2b were 
presented in 25% of the clinical samples in a US study in 2008 (38), while in 2011, this 
co-existence rate was 32.2% in another study from China (39). A recent study in 
experimentally infected pigs indicated that single infection with either PCV2a or PCV2b 
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was not associated with clinical disease but concurrent infection of pigs with both 
genotypes could result in PCVAD (40). 
Geographical distribution: It appears that Europe and North America have been the 
major areas of PCV2 spreading all over the world and, moreover, that PCV2b isolates 
were apparently introduced in North America from Europe (1, 97). High PCV2 
seroprevalence of  >92% has also been reported in Mexico City backyard pigs (98). 
In Asian countries, PCV2 also has a deep impact on the swine industry. In Korea, 
PCVAD is a leading cause for economic concern within the pork industry since the first 
outbreak in 1999; however, only PCV2b strains have been isolated from pigs with 
PMWS since 2005 (93). In China, the genetic variation of Chinese PCV2 strains is 
similar to North American and European strains. The first commercialized vaccine, 
CircoFlex®, was registered in 2009 to control PCV2 infection and PCVAD. Several 
killed vaccines derived from whole virus of some Chinese PCV2 strains were 
subsequently designed and also registered by Chinese local enterprises. These vaccines 
have been applied extensively in controlling PCV2 infection and the manifestations of 
PMWS and other PCVAD (99). From 2011 to 2012, PCV2b was the predominant 
genotype circulating in southern China (108). 
 
Detection	  
To detect the nucleic acids of PCV2, in situ hybridization (ISH) and several kinds of PCR 
have been developed. Multiplex PCR has been used to detect more than one target 
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sequence (PCV1/PCV2, PCV2/PPV, PCV2/pseudorabies virus/PRV) in a single PCR 
reaction (41-44). Nested PCR can increase the ability to detect very small amounts of the 
target sequence (43). Multiplex-nested PCR assay is designed to detect very small 
amounts of several target sequences combining multiplex and nested PCR (45, 46). The 
amount of PCV2 nucleic acids in serum and tissues has been demonstrated to be 
predictive of the clinical manifestations, so that quantitative real-time PCR assays have 
been developed to determine the amount of PCV2 genomic copy numbers in the serum or 
tissues (47, 48). ISH for PCV2 allows localization and quantification of PCV2 but the 
method in general is time consuming and highly expensive (46, 49-51). 
In order to study PCV2 viruses or viral antigens, immunohistochemistry (IHC), electron 
microscopy (EM), virus isolation (VI), and antigen-capture ELISA were developed. 
Virus isolation of PCV2 has been developed in the PK-15 cell line, in which PCV1 was 
discovered (3). However, while VR1BL cells were shown to have higher viral titers than 
PK-15 cells (52). IHC uses polyclonal antibodies to detect PCV2 antigens in formalin-
fixed, paraffin-embedded tissue sections (49, 53). EM is used to demonstrate circovirus-
like particles directly within a cell and to study the virus structure and size (54), but it not 
a routine diagnostic method because it is time consuming and expensive. Antigen-capture 
ELISA on tissue homogenates has been described and the results were found to be 
comparable to quantitative virus isolation and IHC (55). 
There are several ways to detect the anti-PCV2 antibodies, such as indirect 
immunoperoxidase monolayer assay (IPMA), indirect immunofluorescence assay (IFA), 
enzyme-linked immunosorbent assay (ELISA), and seroneutralization (SN) assay. The 
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SN assay has been used to detect the presence of neutralizing antibodies that have the 
ability to prevent virus from attaching to and/or infecting cells (56). IFA detects the 
ability of the antibodies in the serum to bind to a fixed monolayer of PCV2-infected cells 
(6, 41, 57, 58). Recently, a quantitative immunofluorescence assay (QIFA) method was 
established for sero-diagnosis of PCV2 using Vero cells expressing capsid protein of 
PCV2 (59). The IPMA is similar to the IFA with the except that the antibodies are 
peroxidase-conjugated anti-swine IgG (60, 61). 
An ideal diagnostic method must incorporate several features including accuracy, rapid 
testing, low cost, especially when applied to large-scale surveys. In this way, ELISA is 
relatively simple and suitable for screening a large number of sera, although quantitative 
analyses are still limited, considering the serum neutralization assay as a gold standard 
(59). 
A competitive ELISA was designed to test serum for anti-PCV2 antibodies. In that assay 
a cell culture isolate of porcine circovirus type 2 was chosen as antigen and a PCV2-
specific monoclonal antibody as the competing reagent (62). Cap-based ELISA (63-66) 
achieved 88.5% specificity and 89.4% sensitivity for detection of PCV2 antibody in field 
sera (65). Two indirect ELISA were developed based on recombinant PCV2 Cap (rCap) 
and Rep/Rep′ (rRep) proteins expressed in baculovirus and produced in Trichoplusia ni 
insect larvae, which is the first report that rRep ELISA as a new tool to serologically 
distinguish between vaccinated and non-vaccinated animals, at least for those commercial 
vaccines based on the Cap PCV2 protein or inactivated virus (67). 
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Disease	  
The first report of disease related to PCV2 was postweaning multisystemic wasting 
syndrome (PMWS), which was initially described in 1991 in western Canada as a 
sporadic disease, characterized by emaciation, jaundice, enteritis and dyspnea (91). The 
histopathology of the lymphoid tissues of those affected pigs showed a severe lymphoid 
depletion. Many other countries have subsequently reported similar disorders. PMWS is a 
disease of growing pigs with low morbidity but high case mortality, but a causal 
relationship between PMWS and PCV2 had not been elucidated at that time (91). 
PMWS is the most common form of PCVAD and is characterized by wasting, decreased 
weight gain, dyspnea, jaundice and enlarged lymph nodes, as well as degeneration, 
necrosis of hepatocytes, multifocal lymphohistiocytic pneumonia, lymphocytic depletion 
and multinucleated giant cell formation (92, 93). The American Association of Swine 
Veterinarians (AASV) created the concept of porcine circovirus associated-disease 
(PCVAD) in March 2006, in which a connection with PCV2 was involved (12), while in 
Europe, the name of PCVD was used instead (90). Based on the case definition posted by 
AASV in Oct 2006, PCVAD can be subclinical or contain one or more clinical 
manifestations such as multisystemic disease with weight loss, high mortality, respiratory 
signs, porcine dermatitis and nephropathy syndrome (PDNS), enteric signs including 
diarrhea, and reproductive disorders individually or in combination in a herd or group of 
pigs (12). 
PCVAD is a multifactorial disease. Although PCV2 was experimentally examined as the 
etiological agent (94), infection with PCV2 alone does not generally result in clinical 
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disease. Other factors such as variation of virus and host, co-infections and immune 
modulation are considered crucial for development of overt clinical manifestations of 
PCVAD (12). Mutations in amino acid may lead to significant attenuation of the virus, 
but there is no consistent pattern between PCV2 isolates from affected and unaffected 
animals. Pigs of all breeds seem to be equally susceptible to PCV2 infection. Different 
types of adaptive immune response against PCV2 seem related to the level of virus 
replication and clinical manifestation. For management practices, stress and/or other 
potential triggering factors that induce immune stimulation is important in triggering 
PCVAD (95, 96). Besides housing, vaccination schedules, biosecurity, hygiene and 
husbandry practices can modulate the expression of PCVAD. Concomitant viral and 
bacterial infections, such as Porcine reproductive and respiratory syndrome virus 
(PRRSV), porcine parvovirus (PPV) and Mycoplasma hyopneumoniae, with PCV2 can 
increase the incidence of PCVAD (29)(95). 
 
Pathogenesis	  
PCV2 can be transmitted horizontally and vertically. The oronasal route is considered the 
most likely and frequent route of PCV2 transmission, but transmission can also occur 
through direct contact via fecal and urinary routes (87, 88). Breeding animals can also be 
infected with PCV2 via semen from infected boars (89). 
The pathogenesis of PCV2 infection and major cell types that support PCV2 replication 
are still under investigation. After PCV2 infects a cell, the single-stranded DNA (ssDNA) 
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is converted to a double-stranded DNA (dsDNA) intermediate known as the replicative 
form (RF). Under commercial farm conditions, the majority of pigs seroconvert to PCV2 
between 2 and 4 months of age (90). 
The VR1BL cell line was proved to be superior to PK-15 cells for the study of PCV2-
host cell interactions and molecular pathogenesis because it was highly permissible to 
PCV2 infection, induced cellular destruction, and sensitivity to viral load compared to 
PK-15 cell line. (52) 
 
Control	  and	  Prevention	  
Before vaccination was introduced, the control of PCVAD was limited mainly to improve 
management strategies and controlling co-infections. Commercial PCV2 vaccines were 
initially developed to control PMWS, but they are now also used against other PCVAD 
(68). 
Several kinds of vaccines against PCV2 have been designed and tested under 
experimental conditions, such as killed PCV2 vaccine, ORF2 subunit vaccine, DNA 
vaccine, pseudorabies virus expressing ORF1-ORF2 vector vaccine, adeno-ORF2 
expressing vector vaccine, live or inactivated attenuated chimeric PCV2-1 vaccine (18). 
In an evaluation study of PCV2 subunit vaccine, ORF2-encoded capsid protein 
constitutes the major immunogen to induce protection of piglets against a PCV2 
challenge, while ORF1-encoded replication protein was weakly immunogenic (18). 
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ORF2 was chosen because it contains the main neutralizing epitope and thus has potential 
to induce a protective immune response (64, 69). 
There are several commercial vaccines in the market, three of them are subunit vaccines 
based on the PCV2 capsid protein expressed in baculovirus, including Ingelvac 
CircoFLEX® (Boehringer Ingelheim), Circumvent® PCV M (Merck Animal Health, Inc) 
and Porcilis® PCV (MSD Animal Health). The Circovac® vaccine (Merial) is an 
inactivated PCV2 vaccine. The Fostera™ PCV vaccine (Zoetis) is an inactivated 
chimeric PCV1–2 vaccine, redesigned from Suvaxyn® PCV2 One Dose (70)(71, 72). 
Commercially PCV2 vaccines are different in their antigen, adjuvant types, 
recommended animals (sow or piglet or both) and dosage (one or two doses). All 
commercial PCV2 vaccines are based on the PCV2a genotype. Nevertheless, PCV2a-
based vaccines are able to control PCV2b infection in pigs through cross-protection (73). 
However, a recent study showed that a PCV2 vaccine based on genotype 2b is more 
effective than a 2a-based vaccine to protect against PCV2b or combined PCV2a/2b 
viremia in pigs with concurrent PCV2, PRRSV and PPV infection (74). 
Co-existence of PCV2a and PCV2b may result in enhancing of PCV2 replication. A 
study showed an obvious vaccination failure in 30 10-week old pigs, among which only 
50% developed a detectable immune response, putatively indicating a poor vaccine 
efficacy (70). 
Current commercial vaccines have been considered highly effective to inducing 
protective immunity against PCVAD in the field (75-80) and under experimental 
conditions (73, 81, 82). Clear parameters for experimental vaccine evaluation are not 
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sufficient due to lack of consistent, precise animal models for PCVAD. Presence of 
clinical signs, presence of microscopic lesions, presence of PCV2 in lesions, and viral 
load in serum are the most common parameters used for evaluating a PCV2 vaccine (48, 
83), while differences in growth performance in some field trials by different PCV2 
vaccines may also be due to different co-infection, field management, feeding quality and 
production system conditions. 
The efficacy of commercial PCV2 vaccines has not only been tested in PCV2 naïve pigs 
(84) and PCV2 negative pigs (73, 85) in experimental condition, but also in field 
conditions. In a field study, 1542 serum samples were collected from a farm suffering 
from porcine respiratory disease complex (PRDC). PCV2 vaccination decreased the 
PCV2 viral load by 55% to 83% and the mean duration of viremia by 50% (P<0.0001) 
(76). In another study in a herd with a history of PCVAD, PCV2 vaccination reduced the 
mortality by 50% and increased the daily gain in the finishing period (79). In a small 
controlled experimental trial, after challenging with different PCV2 isolates of different 
genotypes and geographic origin, vaccinated pigs had significantly reduced fecal and 
nasal shedding of PCV2 (73). In another controlled experimental study, PCV2 
vaccination reduced PCV2 associated lesions and viremia in pigs concurrently infected 
with PCV2 and PRRSV (84). 
PCV2 viremia has not been detected in dams of PCV2 vaccinated pregnant animals, and 
serum neutralizing antibodies and colostral anti-PCV2 antibodies have also been induced. 
However, PCV2 DNA was detected in colostral samples and individual fetuses following 
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oronasal PCV2 challenge which means vertical transmission of PCV2 can occur in 
PCV2-vaccinated dams (86). 
 
Future	  Study	  
There are still many questions to be answered about PCV2. PCV2 immunology is a great 
challenge area. The nature of the factors that trigger the development of PCVAD is 
largely unknown. Only some individual pigs exhibit clinical signs, while others show no 
clinical signs and they maintain an apparently good performance. Individual expression 
of the disease is a combined result of the virus, the host, the infection timing, and 
management, but the mechanism of each factor is still under investigation. The 
appearance of PCVAD in different countries around the world at almost the same time is 
also a mystery, as well as the genotype shift from PCV2a to PCV2b around the world at 
the same time. 
 
Hypothesis	  
I hypothesized that analysis of anti-capsid and anti-replicate antibodies would enable 
assessment of PCV2 exposure in the United States swine herd. In this study, 2989 serum 
samples from 202 farms in the NAHMS 2012 survey were tested serologically using both 
cap-specific and rep-specific indirect ELISA. Since all the pigs vaccinated during the 5 
years received commercial vaccines based on the capsid protein, and replicase protein is 
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produced only by replicating virus, the comparison of the two ELISA results is expected 
to give us information about infection and vaccination status. These serological results 
are also compared with data from 5 years ago to provide us a historical trend of PCV2 
infection nationwide. 
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Chapter 2 
Materials and Methods 
Indirect	  ELISA	  
Serum samples 
A total number of 5,730 serum samples (30 samples from each farm of 205 farms, from 
13 states) were collected as part of the USDA (United States Department of Agriculture) 
National Animal Health Monitoring System’s (NAHMS) swine 2012 study, which 
focused on operations with 100 or more pigs. Approximately 15 serum samples per farm, 
for a total of 2989 samples from 202 farms, were taken for serological detection. Blood 
was collected from the cranial vena cava or jugular vein and allowed to sit vertically at 
20-24°C for a minimum of 30 min. Samples were cooled to 4°C and shipped on ice 
within 24h to the USDA National Veterinary Services Laboratories (NVSL) in Ames, IA. 
Sera were drawn off, aliquoted, and frozen at -20°C until use (100). 
 
Preparation of cap and rep antigen 
Proteins were made by lab members; PCV2 capsid gene fragments is 549 bp, lacking the 
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amino terminal 39 and carboxyl terminal 10 amino acids, were amplified with BamH1 
and Xho1 restriction enzyme sites. PCV2 cap-specific primers were 5′-
CGCGGATCCATGAAAAATGGCATCTTCAACACCCGCCT-3′ and 5′-
CCGCTCGAGTTCTCTGAATTGTACATACATGGT-3′; PCV2 replicate gene 
fragments is 963bp, were amplified with BamH2 and Xho1 restriction enzyme sites. rep-
specific primers were 5’-CGC GGA TCC ATG CCC AGC AAG AAG AAT G-3’ and 5’-
CCG CTC GAG GTA ATT TAT TTC ATA TGG A-3’ . PCR products were gel purified, 
digested with BamHI and XhoI (New England Biolabs, MA), and cloned into a modified 
pET24b vector (Novagen, Madison, WI) for expression in BL-21 (DE3)-RP cells 
(Stratagene, CA, USA). Gel picture see APPENDIX1. 
 
Choose of non-specific background, positive and negative 
control 
The nonspecific background control was keyhole limpet hemocyanin(KLH). Positive and 
negative controls were chosen from previous PCV2 studies (APPENDIX2). 
 
Indirect ELISA procedure 
Plates were coated with 100ng/well of test antigens (cap/ rep/ KLH) in carbonate buffer 
(15mM Na2CO3, 35mM NaHCO3, pH 9.6) and incubated at 4 °C overnight. Plates were 
then washed three times with phosphate-buffered saline with 0.05% Tween 20 (PBST, 
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pH7.4) at room temperature using an ELISA plate washer. Wells were filled at the end of 
the third wash and allowed to stand for 5 min at room temperature. The plates were then 
washed three more times and tapped on paper towels to remove residual wash buffer. 
Wells were blocked with 300 µl of 5% nonfat dry milk (NFDM), pH 9.6, and the plates 
were incubated at room temperature for two hours. Plates were washed and 100µl of test 
sera, diluted 1:50 in PBST containing 5% NFDM, pH 7.4, in duplicate for one hour. 
Plates were washed, and 100µl of peroxidase labeled goat anti-swine IgG (H+L) (KPL, 
Bethyl Labs), diluted 1:100,000 in PBST with 5% NFDM, pH 7.4, was added to each 
well at room temperature for one hour. The plates were washed four times and color was 
developed with TMB peroxidase substrate and H2O2 (KPL) for 15 min at room 
temperature. Reactions were stopped with 1 M phosphoric acid and plates were read at 
450nm in a ThermoMax microplate reader. Positive results were taken as absorbance 
values >0.1. 
 
Assay repeatability 
Both “intra-assay” and “inter-assay” repeatability was controlled in our indirect ELISA 
methods. Intra-assay repeatability was measured by running the same samples and 
controls on duplicates in the same plate. Inter-assay repeatability was measured by 
involvement of positive and negative serum standards on every plate (100). 
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Statistical methods 
Statistical tests were performed using Prism 6 for Mac OSX (GraphPad Software) and R 
3.0.2 for Mac OS 10.6. Correlations were calculated by Pearson’s correlation. 
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Chapter 3 
Results 
Positive	  and	  negative	  controls	  
Positive and negative controls were chosen from previous PCV2 study. With cut off of 
0.4, three serums above 0.4 were chosen to pool as the positive control. One below 0.4 
was chosen as the negative control (APPENDIX 2). 
 
Determination	  of	  non-­‐specific	  background	  of	  ELISA	  
Keyhole limpet hemocyanin (KLH) is a large, multisubunit, oxygen carrying, 
metalloprotein that is found in the hemolymph of the giant keyhole limpet, Megathura 
crenulata. KLH is a potent immunogenic high-molecular-weight protein, is used 
extensively as a carrier protein in the production of antibodies for research, 
biotechnology and therapeutic applications. I used KLH as our non-specific background. 
To determine the non-specific background, I tested 48 serums with both KLH and blank 
wells (Figure1). The average OD value with KLH is about 0.12. The average OD value 
with blank wells is about 0.08. 
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Selection	  of	  primary	  antibodies	  and	  secondary	  antibody	  
dilutions	  
In order to assess the best distinguishable ELISA results for both Cap and Rep protein to 
determine the serological level of serum, different dilution series of serum antibodies and 
secondary antibodies were measured. I used 1:50, 1:100 and 1:1000 as the dilution 
candidates for primary antibody, while 1:50,000, 1:75,000 and 1:100,000 as the dilution 
candidates for secondary antibody. Two serum positive samples (Yeske 4 and positive 
control) and two serum negative samples (B8-267 and B8-275) were tested for both cap 
and rep in this experiment. Figure 2 A, B and C shows when the secondary antibody 
dilution is 1:50,000, 1:75,000 and 1:100,000, the OD values of those samples in primary 
antibody dilution of 1:50, 1:100 and 1:1000. From these three graphs we can conclude 
that, as the dilution of primary antibody gets higher, the difference of the OD values 
becomes less. For the sake of getting higher recognition level of the sample OD value, I 
choose 1:50 as my sample serum dilution. Although the secondary antibody dilution of 
1:50,000 has the highest recognition level of the OD values, the OD values of negative 
samples are almost 0.1, not low enough to represent my negative results since my non-
specific background is 0.05. Considered of all the influential factors, I decided to use 
1:50 as my primary antibody dilution, while 1:100,000 as my secondary antibody dilution. 
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Correlation	  analysis	  of	  ELISA	  assays	  from	  NAHMS	  swine	  2006	  
and	  NAHMS	  swine	  2012	  
Because I would compare the PCV2 infectious level of NAHMS swine 2012 with 
NAHMS swine 2006, the measurement of the consistency of the two ELISA assays is 
required. The new ELISA assay was tested on serum samples from the NAHMS swine 
2006. 100 serum samples, which were tested seropositively in NAHMS 2006 ELISA 
assay, were chosen to be detected OD values with our new NAHMS 2012 ELISA assay. I 
then compared the OD values of those samples from NAHMS 2006 with NAHMS 2012 
assays, and linear correlation of data from these two assays was presented. The 
coefficiency of the two sets of data is 0.63 (p<0.0001), which is high enough to certificate 
that these two ELISA assays are quite consistent according to the different OD values of 
the same sample set. 
 
Sample	  amount	  for	  NAHMS	  swine	  2012	  ELISA	  test	  
A total amount of 5730 serum samples from 206 farms were collected from USA 
National Animal Health Monitoring System’s (NAHMS) Swine 2012 study which focus 
on operations with 100 or more pigs. Serum samples were taken from up to 30 
grower/finisher market pigs (20-32 weeks of age) from 13 states. In our study, about 15 
samples from each farm were collected, but some farms have more than 15 serum 
samples. Considering some farms have serum samples less than 15, if the sample number 
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is 8 or more, all the serums in that farm were collected. If the serum samples were less 
than 8, those farms were passed. There are totally 2989 serum samples from 202 farms 
(Table 1). 
 
Sample	  level	  prevalence	  results	  from	  ELISA	  testing	  of	  serum	  
samples	  for	  PCV2	  
Since the non-specific background of ELISA result is about 0.1, the cut-off value is 
determined as 2 or 3 times of the non-specific background. Based on the cut-off values of 
0.2, 0.3, sample prevalence can be calculated by the equation: prevalence= number of 
seropositive samples/ total sample number *100% (Table 2). 
 
Farm	  level	  prevalence	  results	  from	  ELISA	  testing	  of	  serum	  
samples	  for	  PCV2	  
Farms with average OD values of serum samples below the cut-off value are considered 
negative farms; with average OD values above the cut-off value are considered positive 
farms (Table 3). 
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Statistical	  analysis	  of	  anti-­‐cap	  ELISA	  and	  anti-­‐rep	  result	  
The distribution of OD values for anti-cap ELISA is extremely right skewed (Figure 4). 
25%, 50%, 75% and 90% percentile are 0.147, 0.216, 0.334 and 0.520, respectively. The 
mean of all samples is 0.278; the standard deviation is 0.199. After taking log 10 of the x-
axis, the values are normally distributed (Figure 5A). 
For anti-rep ELISA, the distribution of OD values is also right skewed (Figure 4). 25%, 
50%, 75% and 90% percentile are 0.111, 0.149, 0.2310 and 0.4045, respectively. The 
mean of all samples is 0.219; the standard deviation is 0.216. After taking log 10 of the x-
axis, the values are normally distributed (Figure 5A). 
 
Comparison	  of	  Cap	  and	  Rep	  in	  2012	  
To demonstrate whether or not there is a significant difference of OD values tested with 
anti-cap ELISA and anti-rep ELISA, a paired t-test was performed. The null hypothesis is 
that there is no difference of these two methods. The alternative hypothesis is that there is 
a difference of these two methods (two tailed). The paired t-test was performed using 
GraphPad Prism 6. The t value is 17.05, p<0.0001, which indicates the null hypothesis 
that the mean difference is zero should be rejected. The data provide sufficient evidence 
that there was a significant mean difference of OD values measured by the capsid-
specific ELISA and replicase-specific ELISA methods (Figure 5B). 
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Relationship	  of	  PCV2	  anti-­‐cap	  and	  anti-­‐rep	  ELISA	  results	  
To analyze the relationship of anti-cap and anti-rep OD values, a scatter plot were 
exhibited based on the both logged anti-cap and anti-rep OD values (Figure 6). 
According to the cut-off of 0.2 and 0.3, the scatter plot is divided into four areas a, b, c 
and d. a represent serum samples with seronegative anti-cap and seropositive anti-rep 
ELISA results, which are experimental errors because it’s biological impossible to have 
presence of Rep but absence of Cap; b indicates those pigs were infected with PCV2 
because anti-Cap and anti-Rep antibodies are both represent at the same time; c stands for 
those pigs were not vaccinated because there is no Cap-specific antibody; d is for serum 
samples with positive anti-cap but negative anti-rep results, implying those pigs were 
vaccinated but not infected because anti-Rep antibody is not present. For cut-off as 0.2, 
there are 135, 805, 1212, 837 serum samples in each area, a, b, c, d, respectively, 4.52%, 
26.93%, 40.55%, 28.00% in percentage respectively; for cut-off as 0.3, there are 109, 378, 
1952, 550 serum samples in each area a, b, c and d, respectively, 3.65%, 12.65%, 65.31%, 
18.40% in percentage respectively. 
 
Comparison	  of	  PCV2	  infection	  level	  in	  2006	  and	  2012	  
Before vaccine has been widely used as a common prevention against PCV2 in 
2006, protection of PCV2 was just focused on facility management and prevention of co-
infection with other pathogens. In NAHMS 2006, anti-cap indirect ELISA test was used 
to give information about infection level together with PCV2 viremia level. Since all 
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commercial vaccines were designed based on Cap protein, the only structure protein of 
PCV2, or the inactivated virus, anti-Cap EILSA result can’t imply the PCV2 infection 
level anymore. In NAHMS 2012, anti-rep ELISA was first used to provide information 
about post-vaccination PCV2 infection level based on the fact that Rep protein is 
produced when PCV2 virus infected and replicated in host cells. In NAHMS 2006, 
78.96% (4756/6234*100%) of all serum samples were tested seropositively using anti-
cap ELISA; while in NAHMS 2012, 16.29% to 31.05% of samples were tested 
seropositively using anti-rep ELISA; but if combined with anti-cap result, as we 
concluded before, the infection level drops down to 12.65% to 26.93%.  Comparing to 
the result of NAHMS2006, we can thus conclude that PCV2 infection level of 2012 in the 
field is lower than in 2006. 
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Figure	  1:	  average	  and	  standard	  deviation	  of	  48	  test	  serums	  with	  
KLH	  and	  blank	  wells.
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Figure	  2:	  Selection	  of	  primary	  antibodies	  and	  secondary	  
antibodies	  dilutions	  
Different dilution combinations of primary antibodies and secondary antibodies for both 
Cap and Rep protein were compared with two seronegative serum samples (B8-267 and 
B8-275) and two seropositive serum samples (Yeske 4 and positive control). (A) Serum 
samples were tested in primary antibody dilution of 1:50, 1:100 and 1:1,000 while 
secondary antibody dilution is 1:50,000. (B) Serum samples were tested in primary 
antibody dilution of 1:50, 1:100 and 1:1,000 while secondary antibody dilution is 
1:75,000. (C) Serum samples were tested in primary antibody dilution of 1:50, 1:100 and 
1:1,000 while secondary antibody dilution is 1:100,000. 
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Figure	  3:	  ELISA	  assay	  result	  correlation	  of	  serum	  samples	  from	  
NAHMS	  swine	  2006	  and	  NAHMS	  swine	  2012.	  	  
The OD values of 100 serum samples from NAHMS swine 2006 were tested both by OD 
values using the new ELISA assay for NAHMS swine 2012 (x-axis) and the previous 
ELISA assay for NAHMS swine 2006 (y-axis). A linear correlation was measured and a 
coefficient of determination (R2) was presented. 
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Figure	  4:	  Frequency	  distribution	  of	  PCV2	  anti-­‐cap	  and	  anti-­‐rep	  
antibody	  levels.	  	  
Distribution of serum samples tested by both cap-specific and anti-rep indirect ELISA 
was presented by histogram with a unit interval OD value of 0.05. 
  
  34 
  
 
0	  
200	  
400	  
600	  
800	  
1000	  
1200	  
0-­‐0.05	   0.1-­‐0.1
5	  
0.20-­‐0.
25	  
0.30-­‐0.
35	  
0.40-­‐0.
45	  
0.50-­‐0.
55	  
0.60-­‐0.
65	  
0.70-­‐0.
75	  
0.80-­‐0.
85	  
0.90-­‐0.
95	   1.0-­‐1.0
5	  
1.10-­‐1.
15	  
1.20-­‐1.
25	  
1.30-­‐1.
35	  
1.40-­‐1.
45	   1.5-­‐1.5
5	  
1.6-­‐1.6
5	  
1.7-­‐1.7
5	  
1.8-­‐1.8
5	  
1.9-­‐1.9
5	  
2.0-­‐2.0
5	  
2.1-­‐2.1
5	  
2.2-­‐2.2
5	  
2.3-­‐2.3
5	  
nu
m
be
r	  
of
	  s
am
pl
es
 
range	  of	  OD	  values 
cap	  rep	  
  35 
Figure	  5:	  Comparison	  of	  PCV2	  anti-­‐cap	  and	  anti-­‐rep	  ELISA	  results.	  
(A) Lognormal distributions of anti-cap and anti-rep ELISA result are graphically 
compared. Blue line represents the distribution of anti-cap ELISA result. Red line 
represents the distribution of anti-rep ELISA result. (B) Box-plot of anti-cap and anti-rep 
ELISA OD values (lognormal). 
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Figure	  6:	  Relationship	  of	  PCV2	  anti-­‐cap	  and	  anti-­‐rep	  ELISA	  
results.	  	  
Relationship of PCV2 anti-cap and anti-rep ELISA results is displayed by two-
dimensional scatter plot of logged anti-cap and anti-rep ELISA OD values. Red lines 
indicate the positive-negative cut-off value for anti-cap and anti-rep ELISA results.  Area 
a stands for serum samples with negative anti-cap ELISA results and positive anti-rep 
ELISA results. Area b stands for serum samples with both positive anti-cap and anti-rep 
ELISA results. Area c stands for serum samples with both negative anti-cap and anti-rep 
ELISA results. Area d stands for serum samples with positive anti-cap ELISA results and 
negative anti-rep ELISA results. All OD values have been taken base-10 log. 
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Table	  1:	  Sample	  and	  farm	  level	  number	  for	  PCV2	  
         Total 
Sample number/farm 17 16 15 13 12 10 9 8  
Number of farms 1 5 186 1 2 4 1 2 202 
Total number 17 80 2790 13 24 40 9 16 2989 
 
 
Table	  2	  Sample	  prevalence	  with	  different	  cut-­‐off	  values	  (%)	  
Cut 
off 
0.2 0.3 
- + - + 
Cap 45.07 54.93 68.95 31.05 
Rep 68.55 31.45 83.71 16.29 
 
 
Table	  3	  Farm	  prevalence	  with	  different	  cut-­‐off	  values	  (%)	  
Cut 
off 
0.2 0.3 
- + - + 
Cap 32.28 67.82 69.31 30.69 
Rep 54.46 45.54 84.16 15.84 
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Chapter 4 
Discussion 
Since globally emerged as one of the severest swine pathogens in the 1990s, studies of 
PCV2 have been continually significant in animal health research. Postweaning 
multisystemic wasting syndrome (PWMS) is the first identified porcine circovirus 
associated disease (PCVAD) in 1991, but the first commercial vaccine was allowed to 
use under special license in 2004. PCV2 is considered as the etiological virus of PCVAD, 
although many other triggers can also have influence on the generation of PCVAD (6). 
Several vaccine types such as DNA vaccine, recombinant subunit vaccine expressing 
viral cap protein and inactivated vaccines have been demonstrated to be immunogenic in 
mice or pigs under experimental condition. PCVAD has also been found effectively 
prevented and controlled by the widely usage of PCV2 vaccination since 2006 in United 
States (12), therefore national investigation of the efficacy of PCV2 vaccination is 
necessary. Yet, to my knowledge, a national-wide investigation of the PCV2 vaccination 
efficacy has not been studied. 
To investigate the prevalence and vaccination status of PCV2 in US swine herd, a total 
amount of 2989 serum samples from 202 farms of 13 states of United States has been 
collected and tested serologically using both cap- and rep-specific indirect ELISA. This is 
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the most up-to-date survey about swine exposure and immune response to PCV2 in the 
United States. 
In present study, in a total of 2989 serum samples, 31.45% - 54.93% were tested 
positively with anti-cap ELISA, while 16.29% - 31.05% positive with anti-rep ELISA. 
Since PCV2 was designed based on cap protein or inactivated virus, while rep protein is 
produced when the virus replicates itself in the cell, different result of anti-cap and anti-
rep indirect ELISA can give us both information about vaccination and infection. 12.65% 
- 26.93% samples with both positive results of anti-cap and anti-rep ELISA indicating 
that the infection level in those samples is not so high. 
In NAHMS 2006 swine study, a total of 6234 serum samples were tested in a capsid-
specific indirect ELISA (2). 78.96% of the samples were tested seropositively and 21.04% 
was seronagetively. Since PCV2 vaccination was not universally applied in field farms 
before 2006, anti-cap ELISA result can implicate the PCV2 infection level of those farms 
because it can reflect the antibody level induced by PCV2; while since 2006, PCV2 
vaccine was widely used in field condition of United States. Our result suggests there is a 
reduction in PCV2 infection level comparing to 2006. Our PCR data has also shown only 
20% to 25% of PCV2 positive viremia (data not shown), a huge decrease comparing to 
82.6% in 2006. It can be suggested that the current PCV2 vaccination has quite good 
efficacy in preventing PCV2. 
In those positive viremia samples, 12% to 15% are PCV2a, 46% to 56% are PCV2b. 
Rests are unknown strains (data not shown). Interestingly, a similar result in experimental 
condition suggested a high negative correlation between PCV2 antibody levels and 
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PCV2b viral load but not for PCV2a, which may reveal a less effective control of PCV2a 
than PCV2b. Possible explanations may involve the inability of the vaccine to induce 
effective neutralizing antibodies against PCV2a, even though all commercial vaccines are 
designed based on PCV2a genotype; or a delayed immune protective response against 
PCV2a compared to PCV2b. 
This investigation doesn’t involve PCV1 as NAHMS 2006 did because PCV1 is proved 
non-pathogenic to swineherds, and recently, PCV2 infection in the pig population has 
been found to be more common than PCV1 infection (83, 102-104). Result from last 
national swine study also show a largely absence of PCV1 in finishing swine (100); while 
PCV2 can cause clinical and subclinical disease contributing the great economic loss in 
swine industry. 
Lack of precise and reproducible animal models for PMWS or PCVAD is one of the 
main hinders to establishing clear parameters for the experimental evaluation of PCV2 
vaccines. Commercial vaccines against PCV2 were initially designed to control PWMS, 
but they can also be used against other PCVAD. Although prevention of the disease is the 
main parameter to evaluate the efficacy of vaccination, the prevention of infection, 
reduce of viremia can also determine the ability of the vaccine to induce immune 
response to reduce PCV2 transmission. 
Efficient PCV2-specific diagnostic tools are necessary to elucidate the infection status. 
PCV2 antibodies can be accurately detected by IIF and IPMA assays (60, 61, 102, 105, 
106), but IIF and IPMA are time and labor consuming for such a large amount of samples. 
Instead, ELISA is easily to apply and also has a relatively high sensitivity and specificity. 
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Several modified ELISAs have been developed to specifically detect the PCV2 
antibodies. PCV2 viral particles were used in a competitive ELISA (c-ELISA) (62) and a 
modified PCV2-based ELISA (64), while more recently recombinant capsid protein 
expressed in baculovirus were used in ORF2 based ELISAs (63, 64), but it is difficult to 
prepare and purify ELISA antigen from PCV2-infected cells and baculovirus. In NAHMS 
2006, it was the first time using a recombinant capsid protein based ELISA to make a 
national wide serological investigation of PCV2 infection. In our NAHMS 2012, we use 
both capsid and replicase based ELISA to investigate the infection level and efficacy of 
vaccination of PCV2. 
Since our ELISA assay is different from the one in 2006, maybe reduction in infection 
level is caused by the different experimental factors comparing to NAHMS 2006. In 
assay part, we use KLH as our non-specific background instead of haptoglobin that was 
the one used in NAHMS 2006. But since KLH and haptoglobin are both have no immune 
response with pigs, they are both good non-background controls. The determination of 
cut off value in ELISA assay is also a challenge of experimental data analysis. I use the 
most common method to determine the cut off value, which is two or three times of the 
non-specific value. The cut-off value may be not so accurate comparing to the real one 
but the range can give us a quite good trend of the results. Although our indirect ELISA 
assay has been demonstrated as the most efficient and accurate serological methods for 
testing antibodies against PCV2 for such a large sample amount, it can just give 
information in serological fact. Other diagnostic methods such as PCR might provide 
more information about viremia. 
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For sample collection part, the number and source of samples are different from NAHMS 
2006. Since the samples are all collected voluntarily from farms national wide, the 
samples in the present study may be from different farms of NAHMS 2006. What’s more, 
the sample size is 6234 in NAHMS 2006 but 2989 in our present study. Those differences 
may also have influence in our evaluation of the vaccination efficacy. The sample amount 
of this present study is large enough but since serum samples were collected voluntarily 
instead of randomly from farms with more than 100 pigs, there may be some restrictions 
about the national wide conclusions. It will also give us more immunological information 
if other samples can be provided such as feces or saliva. The information of those farms 
were confidential, which means no vaccination record or any clinical and subclinical 
PCVAD was provided to study the relationship between the serological result with the 
pathological symptoms. 
Phylogenetic and evolutionary studies are proved to have increasing importance in 
molecular epidemiology of infectious pathogens. Although several genotyping studies 
have been published on PCV2 (8, 27, 107), no evaluation of the utility of the cap or rep 
genes as molecular markers or assessment of potential PCV2 clonality have been 
undertaken. This study is the first one use both cap and rep to design an indirect ELISA 
assay to investigate the infection and vaccination efficacy of PCV2 in US swine herd. 
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APPENDIX 1 
Figure: Gel pictures of cap (A) and rep (B) protein 
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APPENDIX 2 
Figure: Selection positive control from previous PCV2 study with cut-off of 0.4. H/L 16, 
Sow8, Sow 9 strains were chosen and pooled together as the positive control (A). B8-265 
was chosen as the negative control (B). 
 
 
 
 
 
  56 
   A. 
 
 
 
 
 
 
 
 
 
   B 
 
 
 
 
 
  57 
APPENDIX3 
Table: Sample and farm level prevalence from both anti-cap and anti-rep ELISA 
testing for PCV2 of different cut off values 
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a. Sample and farm level prevalence with cut-off of 0.1 
 Sample level prevalence Farm level prevalence 
Cap Rep Cap Rep 
N Percent N Percent N Percent N Percent 
Negative 183 6.12 496 16.59 1 0.5 11 5.4 
Positive 2806 93.88 2493 83.41 201 99.5 190 94.6 
Total 2989 100 2989 100 202 100 202 100 
 
b. Sample and farm level prevalence with cut off of 0.2 
 Sample level prevalence Farm level prevalence 
Cap Rep Cap Rep 
N Percent N Percent N Percent N Percent 
Negative 1347 45.07 2049 68.55 65 32.18 110 54.5 
Positive 1642 54.93 940 31.45 137 67.82 92 45.5 
Total 2989 100 2989 100 202 100 202 100 
 
c. Sample and farm level prevalence with cut off of 0.25 
 Sample level prevalence Farm level prevalence 
Cap Rep Cap Rep 
N Percent N Percent N Percent N Percent 
Negative 1767 59.12 2331 77.99 101 50 147 72.77 
Positive 1222 40.88 658 22.01 101 50 55 27.23 
Total 2989 100 2989 100 202 100 202 100 
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d. Sample and farm level prevalence with cut off of 0.3 
 Sample level prevalence Farm level prevalence 
Cap Rep Cap Rep 
N Percent N Percent N Percent N Percent 
Negative 2061 68.95 2502 83.71 140 69.31 170 84.16 
Positive 928 31.05 487 16.29 62 30.69 32 15.84 
Total 2989 100 2989 100 202 100 202 100 
 
f. Sample and farm level prevalence with cut off of 0.35 
 Sample level prevalence Farm level prevalence 
Cap Rep Cap Rep 
N Percent N Percent N Percent N Percent 
Negative 2301 76.98 2622 16.59 156 77.23 179 88.62 
Positive 688 23.02 367 83.41 46 22.78 23 11.39 
Total 2989 100 2989 100 202 100 202 100 
 
 
 
